JamesHowardMDFAAN

Neurology • Chapel Hill, NC

Neuromuscular Medicine, Neurophysiology

Professor, Neurology, Medicine & Allied Health, University of North Carolina-Chapel Hill School of Medicine

Join to view full profile

Dr. Howard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Howard's full profile

Already have an account?

Office
2200 Houpt Bldg, CB #7025
Chapel Hill, NC 27599
Phone+1 919-962-6680

Fax+1 919-966-2622

Summary

Dr. James Howard is a neurologist in Chapel Hill, NC and is affiliated with University of North Carolina Hospitals. He received his medical degree from The Robert Larner, M.D. College of Medicine at The University of Vermont and has been in practice 43 years. He specializes in neuromuscular medicine and neurophysiology and is experienced in general neurology, electromyography, clinical research, neuromuscular medicine, and clinical neurophysiology.

Education & Training

University of Virginia Medical CenterFellowship, Neuromuscular Medicine (Neurology), 1978 - 1979
University of Virginia Medical CenterResidency, Neurology, 1975 - 1979
Albany Medical CenterInternship, Internal Medicine, 1974 - 1975
University of Vermont College of MedicineClass of 1974

Certifications & Licensure

NC State Medical License 1979 - 2025
VA State Medical License 1978 - 2020
American Board of Psychiatry and Neurology Neurology
American Board of Electrodiagnostic MedicineEMG

Awards, Honors, & Recognition

Lifetime Achievement Award American Association of Neuromuscular and Electrodiagnostic and Medicine, 2024
Distinguished Academic Achievement Award University of Vermont Larner College of Medicine, 2024

Clinical Trials

Mycophenolate Mofetil in Myasthenia Gravis Start of enrollment: 2002 Sep 01
Completed
Phase 3
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Start of enrollment: 2008 Oct 01
Terminated
Phase 2
Efficacy of Methotrexate in Myasthenia Gravis Start of enrollment: 2009 Apr 01
Completed
Phase 2
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis Start of enrollment: 2010 Dec 01
Terminated
Phase 2
The Evaluation of Belimumab in Myasthenia Gravis (MG) Start of enrollment: 2013 Apr 01
Completed
Phase 2
Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Degeneration in Duchenne Muscular Dystrophy Start of enrollment: 2012 Jan 01
Completed
Finding the Optimum Regimen for Duchenne Muscular Dystrophy Start of enrollment: 2013 Jan 01
Completed
Phase 3
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) Start of enrollment: 2013 Dec 01
Completed
Phase 3
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis Start of enrollment: 2014 Nov 12
Completed
Phase 3
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Start of enrollment: 2016 Dec 30
COMPLETED
PHASE2
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis Start of enrollment: 2017 Oct 11
Completed
Phase 2
Disease-Modifying Treatments for Myasthenia Gravis Start of enrollment: 2018 May 07
Completed
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Start of enrollment: 2018 Aug 22
Completed
Phase 3
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) Start of enrollment: 2018 Dec 28
COMPLETED
PHASE3
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. Start of enrollment: 2019 Mar 01
Completed
Phase 3
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis Start of enrollment: 2019 Mar 12
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.
Ali A Habib, Andrew J Klink, Srikanth Muppidi, Anju Parthan, S Chloe Sader
Journal of Neurology. 2024-09-01
2 citations
Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
John F Brandsema, Matthew Ginsberg, Hideki Hoshino, Masakazu Mimaki, Satoru Nagata
Pediatric Neurology. 2024-07-01
1 citations
Evaluating algorithms for identifying incident Guillain-Barré Syndrome in Medicare fee-for-service claims.
Samantha R Eiffert, Brad Wright, Joshua Nardin, James F Howard, Rebecca Traub
Global Epidemiology. 2024-06-01

Press Mentions

Newsworthy from the School of Medicine, Week of December 27 – December 30December 30th, 2021
Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMGOctober 2nd, 2019
Ra Pharmaceuticals Announces Positive Top-Line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia GravisDecember 10th, 2018
Join now to see all